147 related articles for article (PubMed ID: 32552305)
1. Third-line sunitinib treatment in a
Li X; Gao L; Zhang L; Sun H; Gou H
Cancer Biol Ther; 2020 Sep; 21(9):785-789. PubMed ID: 32552305
[TBL] [Abstract][Full Text] [Related]
2. A retrospective case study of sunitinib treatment in three patients with Von Hippel-Lindau disease.
Yuan G; Liu Q; Tong D; Liu G; Yi Y; Zhang J; Zhang Y; Wang LA; Wang L; Chen R; Guan Y; Yi X; Lan W; Jiang J
Cancer Biol Ther; 2018; 19(9):766-772. PubMed ID: 29947576
[TBL] [Abstract][Full Text] [Related]
3. Benefit of Sunitinib in the treatment of pulmonary primitive neuroectodermal tumors: a case report and literature review.
Zhang C; Zhang J; Wang G; Xu J; Li Y; Guo Q; Zheng T; Zhang Y
Oncotarget; 2016 Dec; 7(52):87543-87551. PubMed ID: 27974690
[TBL] [Abstract][Full Text] [Related]
4. First-Line sunitinib in patients with renal cell carcinoma (RCC) in von Hippel-Lindau (VHL) disease: clinical outcome and patterns of radiological response.
Roma A; Maruzzo M; Basso U; Brunello A; Zamarchi R; Bezzon E; Pomerri F; Zovato S; Opocher G; Zagonel V
Fam Cancer; 2015 Jun; 14(2):309-16. PubMed ID: 25391617
[TBL] [Abstract][Full Text] [Related]
5. Sunitinib for the treatment of benign and malignant neoplasms from von Hippel-Lindau disease: A single-arm, prospective phase II clinical study from the PREDIR group.
Oudard S; Elaidi R; Brizard M; Le Rest C; Caillet V; Deveaux S; Benoit G; Corréas JM; Benoudiba F; David P; Gaudric A; Hammel P; Joly D; Timsit MO; Méjean A; Richard S
Oncotarget; 2016 Dec; 7(51):85306-85317. PubMed ID: 27852035
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of VHL, HIF1A, HIF2A, VEGFA and p53 expression in patients with clear‑cell renal cell carcinoma treated with sunitinib as first‑line treatment.
Wierzbicki PM; Klacz J; Kotulak-Chrzaszcz A; Wronska A; Stanislawowski M; Rybarczyk A; Ludziejewska A; Kmiec Z; Matuszewski M
Int J Oncol; 2019 Aug; 55(2):371-390. PubMed ID: 31268155
[TBL] [Abstract][Full Text] [Related]
7. Dynamic epigenetic changes to VHL occur with sunitinib in metastatic clear cell renal cancer.
Stewart GD; Powles T; Van Neste C; Meynert A; O'Mahony F; Laird A; Deforce D; Van Nieuwerburgh F; Trooskens G; Van Criekinge W; De Meyer T; Harrison DJ
Oncotarget; 2016 May; 7(18):25241-50. PubMed ID: 27029034
[TBL] [Abstract][Full Text] [Related]
8. Intrahepatic cholangiocarcinoma: current management and emerging therapies.
Rahnemai-Azar AA; Weisbrod AB; Dillhoff M; Schmidt C; Pawlik TM
Expert Rev Gastroenterol Hepatol; 2017 May; 11(5):439-449. PubMed ID: 28317403
[TBL] [Abstract][Full Text] [Related]
9. Synergy between von Hippel-Lindau and P53 contributes to chemosensitivity of clear cell renal cell carcinoma.
Zhao Z; Chen C; Lin J; Zeng W; Zhao J; Liang Y; Tan Q; Yang C; Li H
Mol Med Rep; 2016 Sep; 14(3):2785-90. PubMed ID: 27485825
[TBL] [Abstract][Full Text] [Related]
10. ZHX2 drives cell growth and migration via activating MEK/ERK signal and induces Sunitinib resistance by regulating the autophagy in clear cell Renal Cell Carcinoma.
Zhu L; Ding R; Yan H; Zhang J; Lin Z
Cell Death Dis; 2020 May; 11(5):337. PubMed ID: 32382017
[TBL] [Abstract][Full Text] [Related]
11. Somatic
Shell J; Patel D; Powers A; Quezado M; Killian K; Meltzer P; Zhu J; Gaitanidis A; Karzai F; Neychev V; Green P; Kebebew E
J Endocr Soc; 2017 Sep; 1(9):1124-1134. PubMed ID: 29264567
[TBL] [Abstract][Full Text] [Related]
12. Targeting FGFR in intrahepatic cholangiocarcinoma [iCCA]: leading the way for precision medicine in biliary tract cancer [BTC]?
Aitcheson G; Mahipal A; John BV
Expert Opin Investig Drugs; 2021 Apr; 30(4):463-477. PubMed ID: 33678096
[No Abstract] [Full Text] [Related]
13. Molecular profiling of intrahepatic cholangiocarcinoma: the search for new therapeutic targets.
Oliveira DV; Zhang S; Chen X; Calvisi DF; Andersen JB
Expert Rev Gastroenterol Hepatol; 2017 Apr; 11(4):349-356. PubMed ID: 28162004
[TBL] [Abstract][Full Text] [Related]
14. Sarcomatoid intrahepatic cholangiocarcinoma in a patient with poor prognosis: a case report and literature review.
Li X; Li J; Liu K; Tan L; Liu Y
J Int Med Res; 2020 Nov; 48(11):300060520969473. PubMed ID: 33161814
[TBL] [Abstract][Full Text] [Related]
15. Advanced Intrahepatic Cholangiocarcinoma: Post Hoc Analysis of the ABC-01, -02, and -03 Clinical Trials.
Lamarca A; Ross P; Wasan HS; Hubner RA; McNamara MG; Lopes A; Manoharan P; Palmer D; Bridgewater J; Valle JW
J Natl Cancer Inst; 2020 Feb; 112(2):200-210. PubMed ID: 31077311
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological restoration of visual function in a zebrafish model of von-Hippel Lindau disease.
Ward R; Ali Z; Slater K; Reynolds AL; Jensen LD; Kennedy BN
Dev Biol; 2020 Jan; 457(2):226-234. PubMed ID: 30825427
[TBL] [Abstract][Full Text] [Related]
17. VHL missense mutations in the p53 binding domain show different effects on p53 signaling and HIFα degradation in clear cell renal cell carcinoma.
Razafinjatovo CF; Stiehl D; Deininger E; Rechsteiner M; Moch H; Schraml P
Oncotarget; 2017 Feb; 8(6):10199-10212. PubMed ID: 28052007
[TBL] [Abstract][Full Text] [Related]
18. Analyses of Potential Predictive Markers and Response to Targeted Therapy in Patients with Advanced Clear-cell Renal Cell Carcinoma.
Song Y; Huang J; Shan L; Zhang HT
Chin Med J (Engl); 2015 Aug; 128(15):2026-33. PubMed ID: 26228213
[TBL] [Abstract][Full Text] [Related]
19. Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.
Calvo E; Schmidinger M; Heng DY; Grünwald V; Escudier B
Cancer Treat Rev; 2016 Nov; 50():109-117. PubMed ID: 27664394
[TBL] [Abstract][Full Text] [Related]
20. Molecular Pathogenesis and Targeted Therapies for Intrahepatic Cholangiocarcinoma.
Moeini A; Sia D; Bardeesy N; Mazzaferro V; Llovet JM
Clin Cancer Res; 2016 Jan; 22(2):291-300. PubMed ID: 26405193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]